2021
Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis
John BV, Dahman B, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Levy C. Rates of decompensation, hepatocellular carcinoma and mortality in AMA‐negative primary biliary cholangitis cirrhosis. Liver International 2021, 42: 384-393. PMID: 34614294, PMCID: PMC8810619, DOI: 10.1111/liv.15079.Peer-Reviewed Original ResearchConceptsLiver-related deathAMA-negative PBCPBC cirrhosisHepatocellular carcinomaMale patientsAMA-positive patientsAMA-positive PBCLiver-related outcomesSimilar unadjusted ratesAnti-mitochondrial antibodiesSimilar ratesNumber of patientsVeterans Health AdministrationRate of decompensationDevelopment of deathUDCA responseOverall deathUnadjusted ratesCirrhosis diagnosisCirrhosisLarge cohortDecompensationPatientsHealth AdministrationNatural history
2016
HIV, Aging, and Viral Coinfections: Taking the Long View
Taddei TH, Re V, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Current HIV/AIDS Reports 2016, 13: 269-278. PMID: 27614654, DOI: 10.1007/s11904-016-0327-7.Books
2012
Exploring beyond cirrhosis
Pinzani M, Groszmann R, Iwakiri Y, Taddei T. Exploring beyond cirrhosis. Hepatology 2012, 56: 778-780. PMID: 22833249, DOI: 10.1002/hep.25775.Peer-Reviewed Original ResearchChronic liver diseaseLiver diseaseComplications of portal hypertensionNatural history of cirrhosisHistory of cirrhosisStage of chronic liver diseaseTreatment of chronic liver diseaseAdvanced stage of chronic liver diseaseGrade of activityAdverse prognosisPortal hypertensionLiver failureHepatocellular carcinomaClinicopathological assessmentStudy groupCirrhosisRisk factorsNatural historyDiseaseEnd stage